SK277922B6 - 2 ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents - Google Patents

2 ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents Download PDF

Info

Publication number
SK277922B6
SK277922B6 SK4035-91A SK403591A SK277922B6 SK 277922 B6 SK277922 B6 SK 277922B6 SK 403591 A SK403591 A SK 403591A SK 277922 B6 SK277922 B6 SK 277922B6
Authority
SK
Slovakia
Prior art keywords
ranitidine hydrochloride
ranitidine
vwd
excipient
2vwd
Prior art date
Application number
SK4035-91A
Other languages
English (en)
Slovak (sk)
Other versions
SK403591A3 (en
Inventor
Derek L Crookes
Original Assignee
Crookes Derek L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK277922(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crookes Derek L. filed Critical Crookes Derek L.
Publication of SK277922B6 publication Critical patent/SK277922B6/sk
Publication of SK403591A3 publication Critical patent/SK403591A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
SK4035-91A 1980-10-01 1991-12-23 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents SK403591A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01

Publications (2)

Publication Number Publication Date
SK277922B6 true SK277922B6 (en) 1995-08-09
SK403591A3 SK403591A3 (en) 1995-08-09

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
SK4035-91A SK403591A3 (en) 1980-10-01 1991-12-23 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents

Country Status (29)

Country Link
US (2) US4521431A (xx)
JP (1) JPS5791983A (xx)
KR (1) KR870001431B1 (xx)
AT (1) AT389696B (xx)
AU (1) AU549119B2 (xx)
BE (1) BE890574A (xx)
CA (1) CA1202638A (xx)
CH (1) CH652122A5 (xx)
CZ (1) CZ280885B6 (xx)
DE (1) DE3139134A1 (xx)
DK (2) DK167794B1 (xx)
ES (1) ES8301954A1 (xx)
FR (1) FR2491067A1 (xx)
GR (1) GR72499B (xx)
HK (1) HK97985A (xx)
IE (1) IE51604B1 (xx)
IL (1) IL63968A (xx)
IT (1) IT1143237B (xx)
KE (1) KE3549A (xx)
LU (1) LU83661A1 (xx)
MY (1) MY8500747A (xx)
NL (1) NL8104482A (xx)
NZ (1) NZ198522A (xx)
PH (2) PH19489A (xx)
PT (1) PT73744B (xx)
SE (1) SE453500B (xx)
SK (1) SK403591A3 (xx)
ZA (1) ZA816809B (xx)
ZW (1) ZW24481A1 (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU45634B (sh) * 1983-07-15 1992-07-20 Richter Gedeon Vegyeszeti Gyar R.T. Postupak za dobijanje hidrohlorida 1-/2-/5-dimetilaminometil-2-(furilmetiltio)-etil /-amino-1-metilamino-2-nitroetilena
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
SK283674B6 (sk) * 1993-03-12 2003-11-04 Pharmacia & Upjohn Company Kryštalická voľná kyselina ceftiofuru a spôsob jej prípravy a farmaceutická kompozícia, ktorá ju obsahuje
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
US5670671A (en) * 1994-04-08 1997-09-23 Brantford Chemicals Inc. Process for the production of an improved form of form 1 ranitidine
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
DE69523447T2 (de) 1994-04-15 2002-05-16 Pharmacia & Upjohn Co., Kalamazoo Kristallformen von 1-[5-methansulfonamidoindolyl-2-carbonyl]-4-[3-[1-methylethylamino]-2-pyridinyl] piperazin
IN181699B (xx) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
IN181698B (xx) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
CN1907967B (zh) * 1994-05-18 2012-07-04 安万特萨博Ⅱ有限公司 抗组胺哌啶衍生物,其多晶形物和假同晶物的无水和水合物形式的制备方法
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0694540B1 (en) 1994-06-24 1998-08-19 Ranbaxy Laboratories Limited Process for the manufacture of form 1 ranitidine hydrochloride
HUT77946A (hu) * 1994-11-18 1998-12-28 Pharmacia & Upjohn Co. Fluor-kinolon-származék fizikailag stabil, szilárd formája
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997035853A1 (en) * 1996-03-25 1997-10-02 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
EP0987256B1 (de) 1997-08-08 2001-10-17 Aventis Pharma Deutschland GmbH Kristallform von N-(4-Trifluormethylphenyl)-5-methylisoxazol-4-carbonsäureamid
US6287693B1 (en) 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) * 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
AR040661A1 (es) * 2002-07-26 2005-04-13 Theravance Inc Diclorhidrato cristalino de n-{2-[-((r)-2-hidroxi-2-feniletilamino)fenil]etil}-(r)-2hidroxi-2-(3-formamido-4-hidroxifenil)etilamina, agonista del receptor adrenergico beta 2
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
CA2504732A1 (en) * 2002-11-08 2004-05-27 Dov Pharmaceutical, Inc. Polymorphs of bicifadine hydrochloride
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) * 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
AU2006275870B2 (en) 2005-07-27 2013-01-10 Otsuka America Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
US7662980B2 (en) * 2006-10-20 2010-02-16 Scinopharm Singapore Pte Ltd. Crystalline forms of docetaxel and process for preparation thereof
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
EP2727912B1 (en) 2011-06-30 2017-04-19 Toray Industries, Inc. Crystals of glycine derivative and pharmaceutical use thereof
CN106397374A (zh) * 2015-05-26 2017-02-15 烟台市华文欣欣医药科技有限公司 一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
IL63968A (en) 1985-10-31
DK436281A (da) 1982-04-02
PH21761A (en) 1988-02-18
SE453500B (sv) 1988-02-08
JPS5791983A (en) 1982-06-08
FR2491067B1 (xx) 1984-09-07
DE3139134C2 (xx) 1990-04-19
AU7595581A (en) 1982-04-08
KE3549A (en) 1985-08-16
CH652122A5 (fr) 1985-10-31
ZA816809B (en) 1983-05-25
LU83661A1 (fr) 1983-06-08
JPH0443070B2 (xx) 1992-07-15
DK33792D0 (da) 1992-03-12
ES505951A0 (es) 1983-01-01
IE51604B1 (en) 1987-01-21
CA1202638A (en) 1986-04-01
DE3139134A1 (de) 1982-05-19
KR870001431B1 (ko) 1987-08-06
AU549119B2 (en) 1986-01-16
IT8149407A0 (it) 1981-10-01
CZ403591A3 (en) 1994-01-19
ZW24481A1 (en) 1983-04-27
BE890574A (fr) 1982-04-01
US4521431A (en) 1985-06-04
NZ198522A (en) 1985-07-12
DK167794B1 (da) 1993-12-13
PT73744A (en) 1981-10-01
SE8105812L (sv) 1982-04-02
MY8500747A (en) 1985-12-31
KR830007070A (ko) 1983-10-14
DK33792A (da) 1992-03-12
ES8301954A1 (es) 1983-01-01
IE812287L (en) 1982-04-01
US4672133A (en) 1987-06-09
PH19489A (en) 1986-05-14
SK403591A3 (en) 1995-08-09
PT73744B (en) 1983-10-31
DK167923B1 (da) 1994-01-03
GR72499B (xx) 1983-11-15
HK97985A (en) 1985-12-13
FR2491067A1 (fr) 1982-04-02
IL63968A0 (en) 1981-12-31
NL8104482A (nl) 1982-05-03
CZ280885B6 (cs) 1996-04-17
AT389696B (de) 1990-01-10
IT1143237B (it) 1986-10-22
ATA422281A (de) 1989-06-15

Similar Documents

Publication Publication Date Title
SK277922B6 (en) 2 ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents
KR940008913B1 (ko) N,n-디메틸-1-[1-(4-클로로페닐)-사이클로부틸]-3-메틸부틸아민 염산염 일수화물의 제조방법
SK285303B6 (sk) Modifikácie 2-amino-4-(4-fluórbenzylamino)-1- etoxykarbonylaminobenzénu, spôsob ich prípravy, ich použitie a liečivá s ich obsahom
US4313949A (en) Method of producing an inhibitory effect on blood platelet aggregation
WO2019063002A1 (zh) 苯烯莫德的晶型及其用途与制备方法
BRPI0616308A2 (pt) novas formas de cristal de cloridrato de irinotecano
SK288052B6 (sk) Polymorph 1 of bilastine, process for preparing thereof, its antihistaminic and antiallergic use and pharmaceutical preparation containing it
CN102321019A (zh) 喹啉化合物的晶形及其生产方法
CN113966332A (zh) Cdk9抑制剂的多晶型物及其制法和用途
DE3781483T2 (de) Pharmazeutische zusammensetzung zum schutz von gehirnzellen.
US4279914A (en) Thrombocyte aggregation inhibiting composition and methods
TWI680983B (zh) 一種鈉－葡萄糖共同轉運蛋白２抑制劑的ｌ－脯胺酸複合物、其一水合物及晶體
KR870000291B1 (ko) 결정상 벤조티아진 디옥사이드 염의 제조방법
EP0944612B1 (en) N-(4-acetyl-1-piperazinyl)-4-fluorobenzamide hydrate
KR101285050B1 (ko) 결정형 1Ｈ-이미다조[4,5-ｂ]피리딘-5-아민,7-[5-[(시클로헥실메틸아미노)-메틸]-1Ｈ-인돌-2-일]-2-메틸, 설페이트 (1:1), 삼수화물 및 이의 약학적 용도
US5663381A (en) Process for preparing form 1 ranitidine hydrochloride
SK278340B6 (en) Separation method of (+)-2-(6-methoxy-2-naphtyl)propionic acid from mixture of (+) and (-)-2-(6-methoxy-2-naphtyl)propionic acids
CH626623A5 (xx)
CN112225732B (zh) 一种盐酸哌罗匹隆水合物晶型及其制备方法
UA121203C2 (uk) Спосіб отримання поліморфної форми стероїдоподібної сполуки
CN112409285A (zh) 噁唑烷酮类化合物的晶型及其制备方法和应用
US3960882A (en) Chemical compounds for trichomoniasis and candidiosis treatment
US2803627A (en) Therapeutic quinoline compounds
US4198414A (en) Compounds and methods for treating diabetic complications
CN116462610A (zh) 一种光学活性二胺衍生物盐的结晶形式及其制备方法